Percutaneous coronary intervention for acute coronary syndromes: No difference in 30-day efficacy or safety of high- and low-dose aspirin; double-dose clopidogrel reduces 30-day risk of cardiovascular death, myocardial infarction or stroke compared with standard dose but increases risk of major bleeding

Anuradha Lala; Jeffrey S. Berger

doi:10.1136/ebm1187

Percutaneous coronary intervention for acute coronary syndromes: No difference in 30-day efficacy or safety of high- and low-dose aspirin; double-dose clopidogrel reduces 30-day risk of cardiovascular death, myocardial infarction or stroke compared with standard dose but increases risk of major bleeding

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	80-81
Number of pages	2
Journal	Evidence-Based Medicine
Volume	16
Issue number	3
DOIs	https://doi.org/10.1136/ebm1187
State	Published - Jun 2011
Externally published	Yes

Access to Document

10.1136/ebm1187

Cite this

Lala, A., & Berger, J. S. (2011). Percutaneous coronary intervention for acute coronary syndromes: No difference in 30-day efficacy or safety of high- and low-dose aspirin; double-dose clopidogrel reduces 30-day risk of cardiovascular death, myocardial infarction or stroke compared with standard dose but increases risk of major bleeding. Evidence-Based Medicine, 16(3), 80-81. https://doi.org/10.1136/ebm1187

Lala, Anuradha ; Berger, Jeffrey S. / Percutaneous coronary intervention for acute coronary syndromes : No difference in 30-day efficacy or safety of high- and low-dose aspirin; double-dose clopidogrel reduces 30-day risk of cardiovascular death, myocardial infarction or stroke compared with standard dose but increases risk of major bleeding. In: Evidence-Based Medicine. 2011 ; Vol. 16, No. 3. pp. 80-81.

@article{503c3def567e40e0954907dbbec09827,

title = "Percutaneous coronary intervention for acute coronary syndromes: No difference in 30-day efficacy or safety of high- and low-dose aspirin; double-dose clopidogrel reduces 30-day risk of cardiovascular death, myocardial infarction or stroke compared with standard dose but increases risk of major bleeding",

author = "Anuradha Lala and Berger, {Jeffrey S.}",

year = "2011",

month = jun,

doi = "10.1136/ebm1187",

language = "English",

volume = "16",

pages = "80--81",

journal = "Evidence-Based Medicine",

issn = "1356-5524",

publisher = "BMJ Publishing Group",

number = "3",

}

Lala, A & Berger, JS 2011, 'Percutaneous coronary intervention for acute coronary syndromes: No difference in 30-day efficacy or safety of high- and low-dose aspirin; double-dose clopidogrel reduces 30-day risk of cardiovascular death, myocardial infarction or stroke compared with standard dose but increases risk of major bleeding', Evidence-Based Medicine, vol. 16, no. 3, pp. 80-81. https://doi.org/10.1136/ebm1187

Percutaneous coronary intervention for acute coronary syndromes: No difference in 30-day efficacy or safety of high- and low-dose aspirin; double-dose clopidogrel reduces 30-day risk of cardiovascular death, myocardial infarction or stroke compared with standard dose but increases risk of major bleeding. / Lala, Anuradha; Berger, Jeffrey S.
In: Evidence-Based Medicine, Vol. 16, No. 3, 06.2011, p. 80-81.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Percutaneous coronary intervention for acute coronary syndromes

T2 - No difference in 30-day efficacy or safety of high- and low-dose aspirin; double-dose clopidogrel reduces 30-day risk of cardiovascular death, myocardial infarction or stroke compared with standard dose but increases risk of major bleeding

AU - Lala, Anuradha

AU - Berger, Jeffrey S.

PY - 2011/6

Y1 - 2011/6

UR - http://www.scopus.com/inward/record.url?scp=79956330069&partnerID=8YFLogxK

U2 - 10.1136/ebm1187

DO - 10.1136/ebm1187

M3 - Comment/debate

AN - SCOPUS:79956330069

SN - 1356-5524

VL - 16

SP - 80

EP - 81

JO - Evidence-Based Medicine

JF - Evidence-Based Medicine

IS - 3

ER -

Lala A, Berger JS. Percutaneous coronary intervention for acute coronary syndromes: No difference in 30-day efficacy or safety of high- and low-dose aspirin; double-dose clopidogrel reduces 30-day risk of cardiovascular death, myocardial infarction or stroke compared with standard dose but increases risk of major bleeding. Evidence-Based Medicine. 2011 Jun;16(3):80-81. doi: 10.1136/ebm1187